- Home
- CNEY vs SONN Comparison
CNEY vs SONN Comparison
Compare CNEY & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- SONN
- Stock Information
- Founded
- CNEY 2018
- SONN N/A
- Country
- CNEY China
- SONN United States
- Employees
- CNEY N/A
- SONN N/A
- Industry
- CNEY Major Chemicals
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- SONN Health Care
- Exchange
- CNEY Nasdaq
- SONN Nasdaq
- Market Cap
- CNEY 2.1M
- SONN 2.5M
- IPO Year
- CNEY 2021
- SONN N/A
- Fundamental
- Price
- CNEY $0.13
- SONN $1.26
- Analyst Decision
- CNEY
- SONN Strong Buy
- Analyst Count
- CNEY 0
- SONN 2
- Target Price
- CNEY N/A
- SONN $38.00
- AVG Volume (30 Days)
- CNEY 504.6K
- SONN 37.4K
- Earning Date
- CNEY 01-01-0001
- SONN 05-13-2025
- Dividend Yield
- CNEY N/A
- SONN N/A
- EPS Growth
- CNEY N/A
- SONN N/A
- EPS
- CNEY N/A
- SONN N/A
- Revenue
- CNEY $50,957,974.00
- SONN $1,000,000.00
- Revenue This Year
- CNEY N/A
- SONN N/A
- Revenue Next Year
- CNEY N/A
- SONN N/A
- P/E Ratio
- CNEY N/A
- SONN N/A
- Revenue Growth
- CNEY N/A
- SONN 674.14
- 52 Week Low
- CNEY $0.12
- SONN $1.22
- 52 Week High
- CNEY $1.60
- SONN $16.80
- Technical
- Relative Strength Index (RSI)
- CNEY 32.47
- SONN 39.32
- Support Level
- CNEY $0.12
- SONN $1.33
- Resistance Level
- CNEY $0.14
- SONN $1.35
- Average True Range (ATR)
- CNEY 0.01
- SONN 0.09
- MACD
- CNEY 0.00
- SONN 0.00
- Stochastic Oscillator
- CNEY 28.97
- SONN 34.00
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.